2008
2007
- Reported $80 million in revenue in 2007
- Received FDA approval of FACTIVE for five-day treatment of mild to moderate community-acquired pneumonia
- Announced launch of FACTIVE in Canada by Abbott Canada
- Sublicensed rights to FACTIVE in Europe to Menarini Group
2006
- Announced launch of FACTIVE-5 in Mexico by Pfizer Mexico
- Acquired cardiovascular therapy ANTARA® (fenofibrate) capsules
- Assigned commercialization rights to FACTIVE in Canada to Abbott Canada
- Announced Approval of FACTIVE®-5 in Mexico
- Hired Philippe M. Maitre, Former CFO of PPD and Former Deputy CFO of Aventis, as Senior Vice President and Chief Financial Officer
- Acquired expanded worldwide rights to lead clinical candidate Ramoplanin
- Sublicensed commercialization rights to FACTIVE in Mexico to Pfizer
2005
- Obtained Special Protocol Assessment from the FDA for Ramoplanin
- Submitted sNDA to FDA for five-day treatment of new indications for FACTIVE® tablets
- Released full results from Phase III trial comparing five-day and seven-day treatment of FACTIVE® Tablets for community-acquired pneumonia
- Named David K. Stone Chairman of the Board of Directors
- Completed enrollment in the pivotal Phase III trial of FACTIVE for the potential 5-day treatment of community-acquired pneumonia
- Hired Nick Colangelo as Senior Vice President of Corporate Development and Operations
2004
- Launched FACTIVE tablets for treatment of key lower respiratory tract infections
- Released preliminary results of Phase II trial of Ramoplanin for C. difficile-associated diarrhea
- Changed stock ticker on Nasdaq to OSCI
- Announced plans to pursue 5-day dosing of FACTIVE® tablets for community-acquired pneumonia
- Completed enrollment in Phase II trial of Ramoplanin for C. difficile-associated diarrhea
- Changed name to Oscient Pharmaceuticals to better reflect focus on product development and commercialization
- Received marketing approval for FACTIVE® tablets in Canada
- Granted Fast Track status from FDA for Ramoplanin for the potential treatment of C. difficile-associated diarrhea
- Completed merger with Genesoft Pharmaceuticals to form commercial-stage pharmaceutical company